NeOnc reports Q1 net loss $8.8M; NEO212 Phase 1 complete, NEO100 interim data Aug 2026

NEONC TECHNOLOGIES HOLDINGS, INC.

2026-Q1 EPS reported -$0.38 vs consensus -$0.22 ▼ miss (-69.3%)

Net loss $8.8M ($0.38/diluted) vs $32.3M ($1.78) in Q1 2025; G&A down to $489K, R&D up to $1.29M.
Cash $138,601 at Mar 31; $10M PIPE from Cinctive Capital and $10M undrawn credit line fund ops into Sep 2026.
NEO212 Phase 1 complete, RP2D set at 610 mg; FDA End-of-Phase 1 meeting planned for potential registrational Phase 2.
NEO100 Phase 2a fully enrolled in IDH1-mutant high-grade glioma; interim data readout expected August 2026.
Appointed David Choi as CAO; CEO Amir Heshmatpour purchased >$500k of NTHI shares in open market.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

NEONC TECHNOLOGIES HOLDINGS, INC. reported first quarter ended March 31, 2026 results: net income $8.8 million or $(0.38) per diluted share, EPS $(0.38) per diluted share.

Period: first quarter ended March 31, 2026
Net income: $8.8 million or $(0.38) per diluted share
EPS: $(0.38) per diluted share
Result: reported results

Exact text from the filing

NeOnc Provides Business Update and Reports Q1 2026 Financial Results

View on SEC.gov

Browse all earnings releases →

NEONC TECHNOLOGIES HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001829126-26-005421

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.